Switch theme
Sign up to access all valuation multiples
J.B. Chemicals & Pharmaceuticals Ltd is an India-based pharmaceutical company. It manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs). The company's products include various pharmaceutical dosage forms like tablets, injectable, creams, ointments, lozenges, herbal liquids, and capsules. It also offers services including optimization of formulations, scale-up services, stability testing, regulatory support, packaging design, and commercial production. The group derives revenue from the manufacturing and marketing of a diverse range of pharmaceutical products. The company sells its products in India and also exports them to other international countries.
1976
5.3K+
LTM Revenue $461M
LTM EBITDA $123M
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
J.B. Chemicals & Pharma has a last 12-month revenue of $461M and a last 12-month EBITDA of $123M.
In the most recent fiscal year, J.B. Chemicals & Pharma achieved revenue of $400M and an EBITDA of $108M.
J.B. Chemicals & Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See J.B. Chemicals & Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $366M | $400M | XXX | XXX | XXX |
| Gross Profit | $180M | $230M | XXX | XXX | XXX |
| Gross Margin | 49% | 57% | XXX | XXX | XXX |
| EBITDA | $82.0M | $108M | XXX | XXX | XXX |
| EBITDA Margin | 22% | 27% | XXX | XXX | XXX |
| Net Profit | $44.8M | $47.6M | XXX | XXX | XXX |
| Net Margin | 12% | 12% | XXX | XXX | XXX |
| Net Debt | n/a | $54.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 21, 2025, J.B. Chemicals & Pharma's stock price is INR 1645 (or $19).
J.B. Chemicals & Pharma has current market cap of INR 256B (or $3.0B), and EV of INR 253B (or $2.9B).
See J.B. Chemicals & Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $3.0B | XXX | XXX | XXX | XXX | $0.51 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 21, 2025, J.B. Chemicals & Pharma has market cap of $3.0B and EV of $2.9B.
J.B. Chemicals & Pharma's trades at 6.4x LTM EV/Revenue multiple, and 23.9x LTM EBITDA.
Analysts estimate J.B. Chemicals & Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for J.B. Chemicals & Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.9B | XXX | XXX | XXX |
| EV/Revenue | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 24.8x | XXX | XXX | XXX |
| P/E | 40.0x | XXX | XXX | XXX |
| P/E/Growth | 2.0x | XXX | XXX | XXX |
| EV/FCF | 43.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJ.B. Chemicals & Pharma's NTM/LTM revenue growth is 13%
J.B. Chemicals & Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $33K for the same period.
Over next 12 months, J.B. Chemicals & Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate J.B. Chemicals & Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for J.B. Chemicals & Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $33K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
J.B. Chemicals & Pharma acquired XXX companies to date.
Last acquisition by J.B. Chemicals & Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . J.B. Chemicals & Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was J.B. Chemicals & Pharma founded? | J.B. Chemicals & Pharma was founded in 1976. |
| Where is J.B. Chemicals & Pharma headquartered? | J.B. Chemicals & Pharma is headquartered in India. |
| How many employees does J.B. Chemicals & Pharma have? | As of today, J.B. Chemicals & Pharma has 5.3K+ employees. |
| Who is the CEO of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's CEO is Mr. Nikhil Ashok kumar Chopra. |
| Is J.B. Chemicals & Pharma publicy listed? | Yes, J.B. Chemicals & Pharma is a public company listed on BOM. |
| What is the stock symbol of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma trades under 506943 ticker. |
| When did J.B. Chemicals & Pharma go public? | J.B. Chemicals & Pharma went public in 1991. |
| Who are competitors of J.B. Chemicals & Pharma? | Similar companies to J.B. Chemicals & Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's current market cap is $3.0B |
| What is the current revenue of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's last 12-month revenue is $461M. |
| What is the current EBITDA of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's last 12-month EBITDA is $123M. |
| What is the current EV/Revenue multiple of J.B. Chemicals & Pharma? | Current revenue multiple of J.B. Chemicals & Pharma is 6.4x. |
| What is the current EV/EBITDA multiple of J.B. Chemicals & Pharma? | Current EBITDA multiple of J.B. Chemicals & Pharma is 23.9x. |
| What is the current revenue growth of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma revenue growth between 2023 and 2024 was 9%. |
| Is J.B. Chemicals & Pharma profitable? | Yes, J.B. Chemicals & Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
